BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Report
Indian Pharma Market is expected to grow largely from non-Covid-19 products’ (chronic/sub chronic and acute therapy products’) sales, as Covid-19 cases receded during Q2 FY22.
In September 2021, the IPM grew at a normalised pace of 12.4% YoY, driven by recovery in acute products’ sales. The acute segment grew at 17.6% YoY while chronic segment improved at 7.3% YoY for September 2021. IPM had increased at a pace of 17.7% YoY in August 2021, preceded by 13.7% YoY growth in July 2021.
In September 2021, higher demand was witnessed for acute therapy products, including respiratory (45.8% YoY) and analgesics (28.1% YoY) in IPM. Similar trend was visible in the respective sub-segments of IPM in July 2021 (anti-infectives growing at 30.2% YoY, analgesic at 24.1% YoY, and respiratory at 22.8% YoY) and August 2021 (respiratory growing at 38.2% YoY, analgesics at 32.4% YoY, and anti-infectives at 29.2% YoY), as well.
On the other hand, pandemic induced lower footfalls to clinics and rising competitive pressures in the generics business are expected to impact the U.S. sales growth. Nevertheless, specialty products’ sales can offset the unfavorable impact in the U.S. market, somewhat.
For Q2 FY22E, we expect our coverage universe to post 3.8% YoY (+0.0% QoQ) growth in sales. Sun Pharma (+10.5% YoY), Dr. Reddy’s (+7.0% YoY), Lupin (+5.3% YoY) and Cipla (5.0% YoY) are expected to post highest growth in revenue in Q2 FY22E.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR